It was observed that NAFLD patients presented significantly higher level of ALT (p < 0.05) in all of subgroups, higher level of AST in the subgroup of ApoE2 (p < 0.05), and higher level of GGT in the subgroup of ApoE4 (p < 0.01). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.